What is the current Price Target and Forecast for ViewRay VRAY

5 Wall Street research analysts have issued 1 year price targets for ViewRay’s shares. On average, they expect the company’s stock price to reach $6.75 in the next twelve months. This suggests a possible upside of 90.7% from the stock’s current price.

Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence . Volume fell together with the price during the last trading day and this reduces the overall risk as volume should follow the price movements.

ViewRay doesn’t possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. As Warren Buffett has famously said, “If you’re not willing to own a stock for 10 years, don’t even think about owning it for 10 minutes.” The best way to realize gains in the… One share of VRAY stock can currently be purchased for approximately $3.54. A $226B Copper Spending JackpotOn November 15, 2021, President Biden signed the biggest infrastructure spending bill of all time.

Bank stocks remain in spotlight — putting in a mixed performance — on Thursday

According to undefined Wall Street analysts, ViewRay’s projected average quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to VRAY previous annual EPS of $NaN . Based on 8 analysts giving stock ratings to VRAY in the past 3 months. You are being directed to ZacksTrade, https://day-trading.info/ a division of LBMZ Securities and licensed broker-dealer. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.

Firstly a stronger fallrate is indicated, but false breaks and “sell-off” may occur. However, a further fall is realistic and any reactions back to the breaking point ($3.81) are considered to be a “second chance” to get out. According to the fan-theory $3.12 will represent the new bottom line of the next trend, but it is far too early to say this for certain. Intraday Data provided by FACTSET and subject to terms of use.

At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.52% per year.

According to analysts’ consensus price target of $6.75, ViewRay has a forecasted upside of 90.7% from its current price of $3.54. In the last two years, ViewRay’s EBITDA has decreased from $-108.20M to $-97.56M – a 9.83% drop. The next year looks promising for ViewRay, with analysts predicting EBITDA of $-101.70M – an increase of 4.24%. Over the next nine years, experts anticipate that ViewRay’s EBITDA will grow at a rate of 4.10%. In the last two years, ViewRay’s Free Cash Flow has fallen from $-87.33M to $-63.65M – a 27.12% decrease.

Forecasting

That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table. Forecst.com predicts future values using technical analysis of a large number of analytical parameters. VRAY stock returns are also predicted based on historical data. Tickergate is an advanced stock research & comparison platform for informed data-driven investment decisions.

Undefined analysts predict VRAY’s average annual Ebitda for undefined to be $NaN, with a high of $NaN and a low of $NaN. ViewRay Inc holds several negative signals and is within a wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. Due to some small weaknesses ingot brokers review and ratings in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Sell to a Strong Sell candidate. Raised $52 million in an initial public offering on the week of April 6th 2015. The company issued 4,000,000 shares at a price of $12.00-$14.00 per share.

Earnings and Valuation

According to 2 wall street analysts, ViewRay’s rating consensus is ‘Buy’. The analyst rating breakdown for VRAY stock is 0 ‘Strong Buy’ (0.00%), 2 ‘Buy’ (100.00%), 0 ‘Hold’ (0.00%), 0 ‘Sell’ (0.00%), and 0 ‘Strong Sell’ (0.00%). On average, 4 Wall Street analysts forecast VRAY’s revenue for 2024 to be $31,353,240,082, with the lowest VRAY revenue forecast at $28,707,063,344, and the highest VRAY revenue forecast at $33,616,171,162.

© 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer. ViewRay’s stock is owned by a variety of retail and institutional investors. Top institutional investors include Artisan Partners Limited Partnership (9.19%), Neuberger Berman Group LLC (5.44%), Group One Trading L.P. (0.00%), Susquehanna International Group LLP (0.00%), Geode Capital Management LLC (1.50%) and Silverarc Capital Management LLC (1.33%).

Be the first to know when Wall Street analysts revise their VRAY stock forecasts and price targets.Get Free VRAY Updates

During the last day, the stock moved $0.135 between high and low, or 3.87%. For the last week, the stock has had daily average volatility of 6.45%. There is no support from accumulated volume below today’s level and given the right condition the stock may perform very badly in the next couple of days. World’s first MRIdian center at Barnes-Jewish Hospital continues to lead the way for advanced precision cancer therapy with MRI-guided radiation DENVER , March 2, 2023 /PRNewswire/ — ViewRay, Inc. (N…

The company was founded by Dinara Akzhigitova in 2004 and is headquartered in Oakwood Village, OH. Real-time analyst ratings, insider transactions, earnings data, and more. ViewRay’s stock was trading at $4.48 at the beginning of 2023. Since then, VRAY shares have decreased by 21.0% and is now trading at $3.54. ViewRay, Inc. designs, manufactures and markets magnetic resonance imaging system.

• Short interest in ViewRay has recently increased by 1.52%, indicating that investor sentiment is decreasing.
• An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s.
• ViewRay’s average quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN.
• The price target is based on several factors, including a company’s earnings, revenue, and valuation.

The ViewRay Inc stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $3.76 and $4.35. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Thursday, February 02, 2023, and so far it has fallen -25.63%.

News Sentiment

ViewRay sees FY23 sees total revenue increase of 25%-40% For FY23, ViewRay anticipates total revenue will increase 25%-40% and adjusted EBITDA in the range of ($70M)-($80M). This info isn’t a recommendation for what you should personally do, so please don’t take the data as investment advice. With no support below and resistance from accumulated volume @ $3.62, some $0.0800 (2.26%) from the current price of $3.54, our system finds the risk reward not very attractive. Prospective multi-center international randomized controlled trial will compare 2-year overall survival in pancreatic cancer patients receiving post-chemotherapy ablative MRIdian SMART vs. chemotherap… Study’s primary objective of low grade 3+ toxicity was met; exploration of secondary outcomes underway to confirm local control rates and patient outcomes with MRIdian SMART DENVER , Oct. 24, 2022 /PR…

The industry with the best average Zacks Rank would be considered the top industry , which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank would place in the bottom 1%. An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s. The Zacks Industry Rank assigns a rating to each of the 265 X Industries based on their average Zacks Rank.

VRAY’s average annual net income forecast represents a NaN% decrease compared to the company’s last annual net income of $NaN . Undefined analysts predict VRAY’s average quarter Ebitda for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than ViewRay’s previous annual Ebitda of $NaN. In 2025, VRAY is forecast to generate $38,033,677,337 in revenue, with the lowest revenue forecast at $38,033,677,337 and the highest revenue forecast at $38,033,677,337. On average, 4 Wall Street analysts forecast VRAY’s earnings for 2024 to be -$70,904,083, with the lowest VRAY earnings forecast at -$89,084,617, and the highest VRAY earnings forecast at -$50,905,495. The stock has broken the wide and falling short-term trend down.

ViewRay Announces Third Quarter 2022 Results

These returns cover a period from January 1, 1988 through February 6, 2023. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month.

Cowen and Company and Stifel acted as the underwriters for the IPO and BTIG and Brean Capital were co-managers. ViewRay issued an update on its FY 2023 earnings guidance on Monday, February, 27th. The company issued revenue guidance of $127.76 million-$143.09 million, compared to the consensus revenue estimate of $136.01 million. The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023. ViewRay has a short interest ratio (“days to cover”) of 10.4, which indicates bearish sentiment. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock.